Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD.

Socié G, Milpied N, Yakoub-Agha I, Bay JO, Fürst S, Bilger K, Suarez F, Michallet M, Lewalle P, Liens D, Mathis C, Guemas E, Vernant JP

Open source

DOI: 10.1182/bloodadvances.2018028282
Published: 2019 Jan 22
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2018028282,
  title = {Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD.},
  author = {Socié G and Milpied N and Yakoub-Agha I and Bay JO and Fürst S and Bilger K and Suarez F and Michallet M and Lewalle P and Liens D and Mathis C and Guemas E and Vernant JP},
  year = {2019},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2018028282},
  url = {https://doi.org/10.1182/bloodadvances.2018028282}
}

RIS

TY  - JOUR
TI  - Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD.
AU  - Socié G
AU  - Milpied N
AU  - Yakoub-Agha I
AU  - Bay JO
AU  - Fürst S
AU  - Bilger K
AU  - Suarez F
AU  - Michallet M
AU  - Lewalle P
AU  - Liens D
AU  - Mathis C
AU  - Guemas E
AU  - Vernant JP
PY  - 2019
JO  - Blood advances
DO  - 10.1182/bloodadvances.2018028282
UR  - https://doi.org/10.1182/bloodadvances.2018028282
ER  -

APA

G, S., N, M., I, Y., JO, B., S, F., K, B., F, S., M, M., P, L., D, L., C, M., E, G., & JP, V. (2019). Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD.. Blood advances. https://doi.org/10.1182/bloodadvances.2018028282

Source records

pubmed · retrieved 2026-09-25T11:37:57.058Z
europe-pmc · retrieved 2026-09-25T11:37:57.063Z
hal · retrieved 2026-09-25T11:37:57.141Z